valproic acid has been researched along with Muscle Disorders in 12 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carnitine deficiency is relatively common in epilepsy; risk factors reportedly include combination antiepileptic drug (AED) therapy with valproic acid (VPA), young age, intellectual disability, diet and enteral or parenteral feeding." | 7.81 | Carnitine deficiency: Risk factors and incidence in children with epilepsy. ( Fukuda, M; Ishii, E; Iwano, S; Kawabe, M; Kikuchi, C; Kuwabara, K; Morimoto, T; Suzuki, Y; Takehara, M; Wakamoto, H, 2015) |
| "Carnitine deficiency is relatively common in epilepsy; risk factors reportedly include combination antiepileptic drug (AED) therapy with valproic acid (VPA), young age, intellectual disability, diet and enteral or parenteral feeding." | 3.81 | Carnitine deficiency: Risk factors and incidence in children with epilepsy. ( Fukuda, M; Ishii, E; Iwano, S; Kawabe, M; Kikuchi, C; Kuwabara, K; Morimoto, T; Suzuki, Y; Takehara, M; Wakamoto, H, 2015) |
| "VPA is widely used for the treatment of generalized epilepsy." | 2.61 | [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy]. ( Araki, M; Mukai, T; Naka, H; Shishido, T; Tokinobu, H; Yamada, H, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (16.67) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Sharma, A | 1 |
| Sinha, S | 1 |
| Narang, A | 1 |
| Chouhan, DK | 1 |
| Gupta, S | 1 |
| Fang, J | 1 |
| Sia, J | 1 |
| Soto, J | 1 |
| Wang, P | 1 |
| Li, LK | 1 |
| Hsueh, YY | 1 |
| Sun, R | 1 |
| Faull, KF | 1 |
| Tidball, JG | 1 |
| Li, S | 1 |
| Yamada, H | 1 |
| Shishido, T | 1 |
| Mukai, T | 1 |
| Araki, M | 1 |
| Naka, H | 1 |
| Tokinobu, H | 1 |
| Fukuda, M | 1 |
| Kawabe, M | 1 |
| Takehara, M | 1 |
| Iwano, S | 1 |
| Kuwabara, K | 1 |
| Kikuchi, C | 1 |
| Wakamoto, H | 1 |
| Morimoto, T | 1 |
| Suzuki, Y | 1 |
| Ishii, E | 1 |
| Al-sharefi, A | 1 |
| Bilous, R | 1 |
| Reiche, I | 1 |
| Tröger, U | 1 |
| Postel, SC | 1 |
| Wolf, R | 1 |
| Bode-Böger, SM | 1 |
| Chabwine, JN | 1 |
| Rossetti, AR | 1 |
| Hirt, L | 1 |
| Kuntzer, T | 1 |
| Schluep, M | 1 |
| Michel, P | 1 |
| Démonet, JF | 1 |
| du Pasquier, RA | 1 |
| Vingerhoets, FG | 1 |
| Kasturi, L | 1 |
| Sawant, SP | 1 |
| Bodensteiner, JB | 1 |
| Morris, HH | 1 |
| Golden, GS | 1 |
| Coulter, D | 1 |
| Trehan, R | 1 |
| Clark, CF | 1 |
| Papadimitriou, A | 1 |
| Servidei, S | 1 |
1 review available for valproic acid and Muscle Disorders
| Article | Year |
|---|---|
[Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
Topics: Aged; Ammonia; Anticonvulsants; Biomarkers; Cardiomyopathies; Carnitine; Consciousness Disorders; Ep | 2019 |
11 other studies available for valproic acid and Muscle Disorders
| Article | Year |
|---|---|
Waddling Gait: A complication of valproate therapy and a thought beyond vitamin D deficiency.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Drug Therapy, Combination; Epilepsy, Absence; Fem | 2020 |
Skeletal muscle regeneration via the chemical induction and expansion of myogenic stem cells in situ or in vitro.
Topics: Animals; Cellular Reprogramming; Colforsin; Culture Media; Fibroblasts; Mice; Muscle, Skeletal; Musc | 2021 |
Carnitine deficiency: Risk factors and incidence in children with epilepsy.
Topics: Adolescent; Anticonvulsants; Cardiomyopathies; Carnitine; Case-Control Studies; Child; Child, Presch | 2015 |
Reversible weakness and encephalopathy while on long-term valproate treatment due to carnitine deficiency.
Topics: Adult; Antimanic Agents; Brain Diseases; Cardiomyopathies; Carnitine; Female; Humans; Hyperammonemia | 2015 |
Valproic acid-induced myopathy in a patient with schizoaffective disorder.
Topics: Aged, 80 and over; Antimanic Agents; Drug Interactions; Female; Humans; Muscular Diseases; Polypharm | 2009 |
[Neurology].
Topics: Antibodies, Monoclonal; Anticonvulsants; Atrial Fibrillation; Carbamates; Chronic Disease; Deep Brai | 2012 |
Sodium valproate -- induced skeletal myopathy.
Topics: Anticonvulsants; Carbamazepine; Carnitine; Child, Preschool; Epilepsy; Humans; Male; Muscular Diseas | 2005 |
Asterixis associated with sodium valproate.
Topics: Adult; Female; Humans; Liver Diseases; Male; Muscular Diseases; Posture; Valproic Acid | 1981 |
Hyperammonemia and asterixis with valproic acid.
Topics: Ammonia; Humans; Muscular Diseases; Valproic Acid | 1981 |
Valproic acid-induced truncal weakness and respiratory failure.
Topics: Aged; Bipolar Disorder; Drug Therapy, Combination; Humans; Male; Muscular Diseases; Respiratory Insu | 1993 |
Late onset lipid storage myopathy due to multiple acyl CoA dehydrogenase deficiency triggered by valproate.
Topics: Acyl-CoA Dehydrogenase; Acyl-CoA Dehydrogenase, Long-Chain; Biopsy; Carnitine; Humans; Lipid Metabol | 1991 |